Rituximab for the treatment of rheumatoid arthritis.

Health technology assessment (Winchester, England)

Volumn 13 Suppl 2, Issue , 2009, Pages 23-29

  Bagust, A ^a   Boland, A ^b   Hockenhull, J ^b   Fleeman, N ^b   Greenhalgh, J ^b   Dundar, Y ^b   Proudlove, C ^b   Kennedy, T ^b   Moots, R ^b   Williamson, P ^b   Dickson, R ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; HUMANS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

MLCS; MLOWN;

EID: 84886943166     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta13suppl2/04     Document Type: Review

References (14)